These include checking for atrophic gastritis in the body of the stomach and fundus, the presence of specific autoantibodies, and levels of substances known as serum pepsinogen I and the ratio of pepsinogen I to pepsinogen II
All GWASs were adjusted for inflation using genomic control, with the inflation factor being no more than 1.035 in all phenotypes
(Ozempic, for example, is approved for diabetes, but the same drug is now available under the name Wegovy as a weight-loss treatment.) Recent trials that studied GLP-1 agonists for weight loss were limited in their size and length, which left a gap in our understanding of the drugs' side effects, the authors wrote in their paper
You dont know whats in it, or how its contaminated
Diabetes Care 48 , 292300 (2025)